Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

se 3 studies (301, 302 and 303), at baseline and at weeks 2, 6 and 13. This OBPM data was pooled and analyzed according to a prospectively designed statistical plan, the objective of which was to evaluate the blood pressure profile of naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 500 mg bid and placebo, in a large OA population.

Both doses of naproxcinod showed a similar blood pressure profile to placebo, as indicated by one-sided 95% confidence intervals (CIs). Naproxen 500 mg bid raised systolic blood pressure (SBP) by 2.0 mmHg compared to placebo, in terms of the mean change between baseline and the average over weeks 2, 6 and 13. Further analyses on these pooled data are ongoing and NicOx plans to disclose more detailed results at leading medical conferences and in peer reviewed scientific publications during 2009 and 2010.

Two additional ABPM studies provided critical, complementary data to the phase 3 program

In November and December, NicOx announced the top-line results of the 111 and 112 clinical pharmacology studies in OA patients with controlled hypertension. These trials were designed to assess the 24-hour blood pressure profile of naproxcinod and two of the most widely used non-steroidal anti-inflammatory drugs (NSAIDs), ibuprofen and naproxen. The state of the art ABPM technique was used, providing critical, complementary data to the phase 3 OBPM data.

    - In the 111 study, 118 patients were randomized to receive naproxcinod
      or naproxen, with escalating doses every three weeks (375, 750 and
      1125 mg bid for naproxcinod, 250, 500 and 750 mg bid for naproxen).
      Over the whole study period, naproxcinod lowered SBP by 2.3 mmHg from
      baseline and naproxen raised it by 1.5 mmHg from baseline.

    - In the 112 study, 299 patients were randomized to receive naproxcinod
      375 mg bid, naproxcinod 750 mg bid, naproxen 250 mg bid, naproxen
      
'/>"/>
SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Senior supply chain management executives from ... the challenges of “Reducing Cost, Lead Time, & Defects ... sourcing. Describing the partnership of the Bio Supply Management ... Institute ( SCMI) of the University of San ... the Kroc Institute of Peace and Justice in San ...
(Date:7/10/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s3bqj2/photonic ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, ... report to their offering. ... photonic integration traces its roots in the latter ... photonic integration went unexplored and unfulfilled for several ...
(Date:7/10/2014)... published today in the journal PNAS (Proceedings of ... time of day and sleep deprivation have a significant ... when looking at the best time of day to ... and for administering medicines effectively. , Researchers from the ... London, investigated the links between sleep deprivation, body clock ...
(Date:7/10/2014)... shelled out for crude 3-D glasses, polarized glasses, ... These basic devices, used to trick the brain ... be rendered obsolete with the introduction of new ... , TAU doctoral students Yuval Yifat, Michal Eitan, ... based on nanoantennas that could be used for ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Time of day crucial to accurately test for diseases, new research finds 2Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3
... Investors to Attend Conference, MONTREAL, Sept. 12 ... announced that Mr. Pierre Laurin, President,and Chief Executive ... Investor Summit on September 16, 2008 at 16:00 ... Hopkins InterContinental Hotel in San Francisco., More ...
... Exosome Diagnostics, Inc. today,announced the appointment of ... this role, Dr. Skog will oversee the research ... diagnostics that can,identify cancer-specific genetic mutations., Dr. ... Exosome Diagnostics,core technology that has been licensed exclusively ...
... Catalyst,Pharmaceutical Partners, Inc. (Nasdaq: CPRX ), ... prescription drugs,for the treatment of drug addiction and ... into definitive agreements with,institutional investors to sell 1,488,332 ... $3.00 per share in a registered direct common ...
Cached Biology Technology:ProMetic to present at Merriman Curhan Ford's Investor Summit 2008 on September 16th 2Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering 2Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering 3
(Date:7/11/2014)... Standards and Technology (NIST) need a special tool ... prove that necessity is truly the mother of ... Lorna De Leoz and Stephen Stein, NIST chemists ... is the study of the abundant, often-branched sugar ... and lipids and influence cellular processes, including immunity, ...
(Date:7/11/2014)... international team of researchers, including scientists from the Max ... a reported a major step in understanding photosynthesis, the ... maintains the oxygen in its atmosphere and which is ... earth. , The researchers report the first direct ... namely the step in which a specific protein complex, ...
(Date:7/11/2014)... mesenchymal stem cells can stimulate neurogenesis in the brain ... (AD) and improve tissue and function injury under the ... the therapeutic effect of adipose-derived stem cells (ADSCs) transplantation ... oxidative injury and neurogenesis in the brain of AD ... Life Sciences, Tsinghua University, China transplanted ADSCs into the ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
... This release is available in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2009-05/bc-pmp051909.php,">Chinese . ... in plants is able to take on a similar ... in the open access journal BMC Microbiology . ... in E. coli cells, polar regions keeping ...
... has been thrown on how humans choose their partners, ... European Society of Human Genetics today (Monday May 25). ... Immunogenetics and Histocompatibility Laboratory at the University of Parana, ... with diverse major histocompatibility complexes (MHCs) were more likely ...
... Molecular Medicine (MDC) Berlin-Buch, Germany, have gained crucial insight ... the sensory neurons of mice, the neurobiologists and pain ... were able to directly elucidate, for the first time, ... were able to show that neurons develop their sensitivity ...
Cached Biology News:Plant Min protein sits tight and rescues E. coli 2Opposites attract -- how genetics influences humans to choose their mates 2Investigating the development of mechanosensitivity 2
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... C-terminus of Human MSY2/YBOX2. (Note: ... (Peptide available as ...
...
Request Info...
Biology Products: